tislelizumab
novartis,beigene
[]
key detail from $bgne $nvs #gi23 tislelizumab presentation: rationale-305 analysis was sequential, starting with pd-l1 5%, and only if this was positive would itt analysis be performed. so it hasn't necessarily failed in all-comers (though likely it has). 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.